Abstract-We investigated the ability of angiotensin II type 1 (AT1) receptor blockers with peroxisome proliferator-activated receptor (PPAR)-␥ agonist activity (telmisartan and irbesartan) and AT1 receptor blockers devoid of PPAR␥ agonist activity (eprosartan and valsartan) to inhibit vascular cell proliferation studied in the absence of angiotensin II stimulation. Telmisartan and, to a lesser extent, irbesartan inhibited proliferation of human aortic vascular smooth muscle cells in a dose-dependent fashion, whereas eprosartan and valsartan did not. To investigate the role of PPAR␥ in the antiproliferative effects of telmisartan, we studied genetically engineered NIH3T3 cells that express PPAR␥. Pioglitazone inhibited proliferation of NIH3T3 cells expressing PPAR␥ but had little effect on control NIH3T3 cells that lack PPAR␥. In contrast, telmisartan inhibited proliferation equally in NIH3T3 with and without PPAR␥. Valsartan failed to inhibit proliferation of either cell line. In addition, telmisartan inhibited proliferation equally in aortic smooth muscle cells derived from mice with targeted knockout of PPAR␥ in the smooth muscle and from control mice, whereas valsartan had no effect on cell proliferation. Telmisartan, but not valsartan, reduced phosphorylation of AKT but not extracellular signal-regulated kinase otherwise induced by exposure to serum of quiescent human smooth muscle cells, quiescent mice smooth muscle cells lacking PPAR␥, or quiescent Chinese hamster ovary-K1 cells lacking the AT1 receptor. In summary, the antiproliferative effects of telmisartan in the absence of exogenously supplemented angiotensin II involve more than just AT1 receptor blockade and do not require activation of PPAR␥. It might be postulated that inhibition of AKT activation is a mechanism mediating the antiproliferative effects of telmisartan, including in cells lacking AT1 receptors or PPAR␥. Key Words: atherosclerosis Ⅲ angiotensin type II receptor blocker Ⅲ cell proliferation Ⅲ PPAR␥ Ⅲ angiotensin II V ascular proliferation is a critical process in the development of atherosclerosis and is associated with other cellular processes in atherogenesis, such as inflammation, apoptosis, and matrix formation. 1 Many mediators are involved in the pathogenesis of vascular proliferation, including growth factors and cytokines, such as platelet-derived growth factor, transforming growth factor-␤, angiotensin II (AII), epidermal growth factor, and insulin-like growth factor 1. 1 Inhibition of AII-mediated vascular proliferation by angiotensin-converting enzyme inhibitors and AII type 1 (AT1) receptor blockers (ARBs) is considered a potential therapeutic mechanism for reducing the risk for atherosclerotic cardiovascular disease beyond just the ability of these drugs to reduce blood pressure. 2 However, because vascular cell proliferation and atherosclerosis can be influenced by many growth factors other than just AII, additional targets for inhibiting vascular cell growth beyond renin-angiotensin system blockade might be useful in maximizing cardiovascular protection.
V ascular proliferation is a critical process in the development of atherosclerosis and is associated with other cellular processes in atherogenesis, such as inflammation, apoptosis, and matrix formation. 1 Many mediators are involved in the pathogenesis of vascular proliferation, including growth factors and cytokines, such as platelet-derived growth factor, transforming growth factor-␤, angiotensin II (AII), epidermal growth factor, and insulin-like growth factor 1. 1 Inhibition of AII-mediated vascular proliferation by angiotensin-converting enzyme inhibitors and AII type 1 (AT1) receptor blockers (ARBs) is considered a potential therapeutic mechanism for reducing the risk for atherosclerotic cardiovascular disease beyond just the ability of these drugs to reduce blood pressure. 2 However, because vascular cell proliferation and atherosclerosis can be influenced by many growth factors other than just AII, additional targets for inhibiting vascular cell growth beyond renin-angiotensin system blockade might be useful in maximizing cardiovascular protection.
Recently, certain ARBs, including telmisartan and irbesartan, have been reported to have partial peroxisome proliferator-activated receptor (PPAR)-␥-activating properties and have been referred to as selective PPAR modulators. [3] [4] [5] Telmisartan has attracted particular attention because of its potential ability to activate PPAR␥ when tested at concentrations that might approach those achieved in plasma with the usual oral dosing. Telmisartan has been reported to increase adiponectin expression in adipocytes, 6 inhibit migration of CD4-positive lymphocytes, 7 delay endothelial cell senescence by regulating endothelial NO synthase production, 8 and increase caloric expenditure and protect against dietary-induced weight gain and hepatic steatosis 9 through mechanisms involving more than just AT1 receptor blockade and possibly via PPAR␥ activation. Recently, we reported that telmisartan can also inhibit vascular cell proliferation through mechanisms that do not appear to depend on the interaction of telmisartan with AT1 receptors. 10 However, pretreatment of vascular cells with the PPAR␥ antagonist GW9662 did not influence the antiproliferative effects of telmisartan, suggesting that the ability of telmisartan to inhibit cell proliferation might not involve activation of PPAR␥. 10 Because GW9662 itself can inhibit cell proliferation 11 and because such pharmacological antagonists can have off-target effects or yield incomplete receptor inhibition, the studies with GW9662 left open the possibility that PPAR␥ activation might still be contributing to the antiproliferative effects of telmisartan. To definitively investigate whether PPAR␥ activation might be required for the antiproliferative effects of telmisartan, we investigated the ability of telmisartan to inhibit the proliferation of cell lines lacking PPAR␥ and explored the potential effects of telmisartan on selected signaling proteins involved in cell pathways that control growth and differentiation.
Materials and Methods

Materials
ARBs were purchased from the pharmacy, purified by highperformance liquid chromatography, and stored as stock solutions as dimethyl sulfoxide in the freezer.
Cell Culture
Human aortic vascular smooth muscle cells (HAVSMCs) and Chinese hamster ovary (CHO)-K1 cells were purchased from the American Type Culture Collection. HAVSMCs were maintained in DMEM/F12 supplemented with 10% FBS (Hyclone) and 1ϫ Antibiotic-Antimycotic Solution (MediaTech, Inc), and CHO-K1 cells were maintained in DMEM supplemented with 10% FBS and 1ϫ Antibiotic-Antimycotic Solution. Human coronary artery smooth muscle cells (HCASMCs) and human umbilical vein endothelial cells (HUVECs) were purchased from Lonza. HCASMCs were maintained in smooth muscle growth medium (Lonza), and HUVECs were maintained in endothelial growth medium 2 (Lonza). NIH3T3 cells stably transduced with the pBABE-Puro vector (NIHBabe cells hereafter referred to as "NIH3T3 controls") or the pBABE-Puro-PPAR␥ vector (NIH-Pparg cells hereafter referred to as "NIH3T3-Pparg cells") were originally produced by Tontonoz et al 12 and obtained from Dr Ron Evans (Salk Institute). NIH3T3 cells were maintained in DMEM supplemented with 5% calf serum (Hyclone), 2 g/mL of puromycin, and 1ϫ Antibiotic-Antimycotic Solution.
Knockout Mice
An expanded Methods section is available in the online Data Supplement, available at http://www.hypertensionaha.org.
Isolation of Smooth Muscle Cells From Pparg Knockout Mice and Controls
Mouse aortic vascular smooth muscle cells were isolated and cultured following the protocol of Guo et al. 13 Briefly, aortas from 5-week-old female smooth muscle Pparg knockout (SMPGKO) mice and control mice were incubated in DMEM containing 1.5 mg/mL of collagenase/Dispase (Roche), 0.5 mg/mL of elastase type II-A (Sigma), 1.0 mg/mL of trypsin inhibitor type I-S (Sigma), and 2.0 mg/mL of BSA (Sigma). After 30 minutes of incubation, the medium was changed to DMEM that contained 1.0 mg/mL of collagenase type II (Sigma), 0.3 mg/mL of trypsin inhibitor type I-S, and 2.0 mg/mL of BSA. The aorta was incubated for 30 minutes. The cellular digests were filtered through sterile 100-m nylon cell strainers, centrifuged at 300g for 10 minutes, and washed twice before culture in DMEM/F12 (University of California San Francisco Cell Culture Facility) containing 10% FBS (Hyclone) and antibiotics. All of the incubations in the enzyme solutions were carried out in 95% air/5% CO 2 at 37°C. The study protocol was approved by the institutional animal care and use committee at the University of California San Francisco and was conducted in accordance with National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Confirmation of Pparg Knockout in Smooth Muscle Cells
To confirm deletion of Pparg sequences flanked by loxP sites, RNA was extracted from vascular smooth muscle cells of SMPGKO and control mice using the RNAqueous-4PCR kit (Ambion). cDNA was synthesized using the SuperScript first-strand synthesis system (Invitrogen). Primers that distinguish the full-length (700-bp) and recombined (300-bp) transcripts of Pparg1 were used according to the previous report 14 (forward primer in 5Ј untranslated region: 5Ј-GTCACGTTCTGACAGGACTGTGTGAC-3Ј; reverse primer in exon 4: 5Ј-TATCACTGGAGATCTCCGCCAACAGC-3Ј).
Stepdown PCR was performed, and the products were electrophoretically separated on 7% polyacrylamide gel.
Cell Proliferation Assay
HAVSMCs, HUVECs, HCASMCs, NIH3T3 cells, and mouse aortic vascular smooth muscle cells were plated at 1ϫ10 4 to 5ϫ10 4 cells per well in the indicated medium. After attachment, cells were exposed to ARBs dissolved in DMSO, which were added in the same growth medium. Untreated cells not exposed to ARBs were incubated with an equivalent volume of DMSO added in the medium. Cells were treated with the indicated drugs for 5 to 7 days, and the medium containing drugs was changed twice. After 5 to 7 days, cells were trypsinized and cell numbers were counted using a hemacytometer.
Detection of Cell Signaling Proteins
We used Western blot analysis to detect effects of telmisartan or valsartan on serum-induced changes in phospho-AKT and phosphop44/42 mitogen-activated protein kinase (extracellular signal-regulated kinase [ERK] 1 and ERK2) levels in vascular smooth muscle. Cells were made quiescent with low serum medium (0.25% FBS) or medium without serum, including telmisartan, valsartan, or DMSO vehicle for 24 hours, and were then changed to medium with 10% FBS. After 10 minutes, cells were washed twice with cold PBS and lysed with cell lysis buffer (Thermo Scientific) supplemented with complete mini-protease inhibitor mixture (Roche). After a centrifugation at 15 000g for 10 minutes, protein concentration was measured with the Dc Protein assay kit (BioRad). Twenty-microgram aliquots of protein were separated by polyacrylamide-10% SDS gel electrophoresis and transferred to nitrocellulose membranes (Amersham). After blocking with 5% skim milk, membranes were incubated with either phospho-AKT antibody that detects endogenous levels of AKT phosphorylated at Thr308 (Cell Signaling Technology, No. 5106) or phospho-ERK antibody that detects endogenous levels of p44 and p42 mitogen-activated protein kinase (ERK1 and ERK2) when phosphorylated either individually or dually at Thr202 and Tyr204 of ERK1 or Thr185 and Tyr187 of ERK2 (Cell Signaling Technology, No. 9101). This was followed by incubation with either antimouse secondary antibody or antirabbit secondary antibody, respectively. Chemiluminescent signals were generated by ECL-plus (Amersham). After removal of the antibodies using the Restore buffer (Pierce), the membranes were subjected to immunodetection of total AKT using AKT antibody (Cell Signaling Technology, No. 9272) or total ERK using total ERK antibody (Cell Signaling Technology, No. 9102). Signal intensities of the bands were analyzed by Multi Gauge software (Fuji Film), and the ratio of the signal intensity of phospho-AKT or phospho-ERK to that of total AKT or total ERK was calculated to determine the relative amounts of phospho-AKT or phospho-ERK, respectively.
Statistical Analysis
Data are expressed as meanϮSEM. To compare cell numbers, statistical analysis was performed by 1-way ANOVA and the Holm-Sidak procedure to adjust for multiple comparisons of individual data groups against the control.
Results
Effect of ARBs on Cell Proliferation in Human Vascular Cells
We compared the effects of telmisartan, irbesartan, valsartan, and eprosartan on the spontaneous growth of human vascular cell lines under conditions in which the cells had not been supplemented with exogenous AII to stimulate proliferation. Three cell lines (HAVSMCs, HUVECs, and HCASMCs) were treated with different ARBs at a concentration of 10 mol/L for 7 days and the cell numbers were counted. Telmisartan inhibited cell proliferation in all 3 of the cell lines, whereas the other ARBs had no effect on cell numbers (Figure 1 ). To test for dose-dependent effects of ARBs on cell proliferation, HAVSMCs were treated with ARBs at various concentrations from 0.625 to 80.000 mol/L. Telmisartan, a known partial agonist of PPAR␥, inhibited cell proliferation in a dose-dependent fashion starting at concentrations between 2.5 and 5.0 mol/L (Figure 2 ). Irbesartan, a less potent partial agonist of PPAR␥ than telmisartan, attenuated cell proliferation starting at a concentration of Ϸ10.0 mol/L. In contrast, 2 ARBs devoid of activity on PPAR␥, eprosartan and valsartan, had no effect on cell proliferation even when tested at concentrations as high as 80.0 mol/L.
Effect of Telmisartan on Cell Proliferation in NIH3T3 Cells Expressing or Not Expressing PPAR␥
To determine whether the antiproliferative effects of telmisartan depend on PPAR␥, we studied NIH3T3 cells lacking PPAR␥ and NIH3T3 cells stably expressing PPAR␥. 12 Figure  4 shows the effects of telmisartan and valsartan on proliferation of NIH3T3-PPAR␥ cells and NIH3T3-control cells in continuous culture (Figure 3 ). Experiments were also performed in cells treated with the PPAR␥ agonist pioglitazone as a positive control. Antiproliferative effects of pioglitazone were significantly greater in NIH3T3 cells expressing PPAR␥ compared with NIH3T3 cells lacking PPAR␥. In contrast, the 
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antiproliferative effects of telmisartan in NIH3T3 cells lacking PPAR␥ were similar to those in NIH3T3 cells expressing PPAR␥. These findings raised the possibility that telmisartan might also have the ability to inhibit the proliferation of vascular smooth muscle cells in the absence of PPAR␥.
Effect of Telmisartan on Cell Proliferation in PPAR␥-Deleted Vascular Smooth Muscle Cells
To directly determine whether the antiproliferative effect of telmisartan in vascular smooth muscle cells requires PPAR␥, we studied aortic vascular smooth muscle cells from SMPGKO mice and their littermate controls. Successful deletion of exons 1 and 2 of PPARg in the SMPGKO mice was confirmed by RT-PCR (Figure 4 ). Pioglitazone (10 mol/L) significantly inhibited proliferation of vascular smooth muscle cells isolated from control mice but not in cells isolated from SMPGKO mice ( Figure 5 ). Valsartan failed to inhibit proliferation in both knockout and control cells. However, 10 mol/L and 20 mol/L of telmisartan inhibited proliferation equally in cells isolated from SMPGKO mice and controls ( Figure 5 ).
Effect of Telmisartan on Phosphorylation of AKT and ERK
Activation of AKT and ERK signaling by phosphorylation plays a key role in cell proliferation in response to growth stimuli. 15, 16 Therefore, we investigated the effects of different ARBs on the phosphorylation of AKT and ERK in HAVSMCs stimulated with 10% serum for 10 minutes after 24-hour cellular quiescence. As shown in Figure 6 , the relative amount of AKT phosphorylated at Thr 308 was decreased by treatment with telmisartan beginning at concentrations of 2.5 to 5.0 mol/L, whereas valsartan had no effect on the relative phosphorylation of AKT. Relative phosphorylation of ERK was not affected by treatment with either telmisartan or valsartan. To confirm that the inhibition of AKT phosphorylation by telmisartan involves more than AT1 receptor blockade, CHO-K1 cells that lack AT1 receptor were studied. As shown in Figure 6B , telmisartan, but not valsartan, inhibited the relative phosphorylation of AKT. AKT signaling was also compared between smooth muscle cells from SMPGKO mice and control mice to determine whether PPAR␥ signaling is involved in the activation of AKT. As shown in Figure 6C , telmisartan inhibited phosphorylation of AKT equally in cells from SMPGKO mice and from control mice, reflecting PPAR␥-independent effects of telmisartan on AKT activation.
Discussion
In the current study, we investigated the ability of 4 different ARBs to inhibit proliferation of 3 different vascular cell lines of human origin in the absence of supplemental amounts of exogenously added AII. Two of the ARBs tested, telmisartan and irbesartan, are known to have partial agonist activity on PPAR␥, whereas the other 2 ARBs tested, eprosartan and valsartan, have little or no effect on PPAR␥ activity. 3 Telmisartan inhibited vascular cell proliferation in a dosedependent fashion beginning at concentrations of 2.5 to 5.0 mol/L, and irbesartan showed antiproliferative effects when tested at concentrations Ͼ10.0 mol/L. In contrast, eprosartan and valsartan had no effect on the proliferation of human aortic vascular smooth muscle cells even when tested at concentrations Յ80 mol/L, which exceed the levels ordinarily required for robust AT1 receptor blockade. Recently, we reported that telmisartan also dose-dependently inhibited the proliferation of rat vascular smooth muscle cells in the absence of exogenously supplemented AII, whereas ARBs with relatively little or no effect on PPAR␥ activity did not inhibit cell proliferation. 10 In addition, we found that telmisartan inhibited the proliferation of CHO-K1 cells that lack AT1 receptors. 10 Taken together, these observations are consistent with the possibility that the antiproliferative effects of telmisartan involve more than just its ability to block AT1 receptors or otherwise interact with AT1 receptors. Other investigators have demonstrated that some ARBs can act as inverse agonists and influence certain AII-independent activities of the AT1 receptor. 17 Given that telmisartan can inhibit proliferation of cells lacking AT1 receptors, it appears that the antiproliferative effects of telmisartan may also go beyond inverse agonism of AT1 receptors. In addition, valsartan, an ARB with known inverse agonist activity, appeared to have relatively little or no ability to inhibit vascular cell proliferation in the absence of AII stimulation.
Given that ARBs with PPAR␥ agonist activity inhibit proliferation of vascular smooth muscle cell lines in the absence of exogenously supplemented AII, whereas ARBs relatively devoid of PPAR␥ activity do not, it has been suggested that PPAR␥ might be playing a role in the antiproliferative effects of molecules like telmisartan. However, because of recent studies showing that telmisartan could inhibit cell proliferation when tested in the presence of a pharmacological inhibitor of PPAR␥, the role of PPAR␥ in the antiproliferative effects of ARBs like telmisartan has been uncertain. 10 In the current studies, we used a genetic approach to directly test whether the antiproliferative effects of telmisartan require the presence of PPAR␥. This was accomplished by studying NIH3T3 cells that do not express PPAR␥ and by studying vascular smooth muscle cells from mice with targeted knockout of PPAR␥ in smooth muscle. Our findings show that telmisartan, but not valsartan, has the capacity to inhibit proliferation of cells with or without PPAR␥.
The fact that telmisartan can inhibit cell proliferation in the absence of the AT1 receptor or in the absence of PPAR␥ might suggest that the antiproliferative effects of telmisartan observed in these studies do not depend on the presence of either the AT1 receptor or PPAR␥. However, an alternative 
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possibility is that, under the conditions of our studies, the antiproliferative effects of telmisartan require the presence of at least one or the other of these receptors. To investigate this possibility, it will be necessary to test the antiproliferative effects of telmisartan in a double-knockout cell line that lacks both the AT1 receptor and PPAR␥, as well as in an otherwise identical control line that expresses one or both of these receptors. In any case, on the basis of previous results and those of the current studies, it now seems clear that the antiproliferative effects of telmisartan involve more than just AT1 receptor blockade and do not require the presence of PPAR␥.
In these studies, we further explored potential mechanisms of the antiproliferative effects of telmisartan by investigating its impact on activation of AKT and ERK, 2 key proteins involved in important signaling pathways controlling growth and differentiation. Angiotensin receptor blockade is known to inhibit the ability of supplemental AII to activate AKT and ERK. 18 In addition, Zou et al 19 have shown that, in cardiomyocytes, candesartan can inhibit increases in ERK phosphorylation induced by mechanical stretch in the absence of AII. However, the effects of ARBs on AKT and ERK activation in vascular smooth muscle cells not deliberately stimulated with AII have not been well studied. We have found that telmisartan but not valsartan inhibits activation of AKT but not ERK in vascular smooth muscle cells in the absence of growth stimulation by supplemental amounts of AII. Telmisartan also inhibited activation of AKT in CHO-K1 cells that lack AT1. These findings suggest that the capacity of telmisartan to inhibit AKT activation involves more than just AT1 receptor blockade. We also found that telmisartan can inhibit activation of AKT in smooth muscle cells that lack PPAR␥. Akt is a protooncogene with a critical regulatory role in diverse cellular processes, including growth, survival, and the cell cycle. 15,20 -22 Akt is also a major regulator of insulin signaling and glucose metabolism, and it is activated by phosphorylation at Thr 308 or Ser373, downstream of phosphatidylinositol 3-kinase signaling. Direct targets of telmisartan that result in inhibition of AKT activation remain unknown. Thus, the current findings raise the possibility that inhibition of AKT activity may be a mechanism mediating the antiproliferative effects of telmisartan, including in cells that lack the AT1 receptor or PPAR␥, and should motivate future studies on the impact of telmisartan on AKT-related pathways beyond just its ability to block AT1 receptors or activate PPAR␥.
Perspectives
It has become increasingly apparent that some ARBs have distinct effects on cellular mechanisms involving more than just AT1 receptor blockade, and that could theoretically contribute to their ability to protect against cardiovascular and metabolic diseases. However, the clinical significance of these cellular effects beyond AT1 receptor blockade remains uncertain, because large-scale, clinical outcome trials based on head-to-head comparisons of different ARBs have never been conducted. In the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial in patients at high risk for cardiovascular disease, clinical outcomes in patients treated with telmisartan were similar to those in patients treated with the angiotensin-converting enzyme inhibitor ramipril. 23 However, angiotensin-converting enzyme inhibitors are also known to influence cardioprotective mechanisms that involve more than just inhibition of the renin-angiotensin system, including effects on bradykinin and NOrelated pathways. Thus, the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial could not address whether ARBs like telmisartan provide added clinical benefits beyond those mediated by their ability to inhibit the renin-angiotensin system, because the comparator drug, ramipril, also exerts effects beyond just inhibition of the renin-angiotensin system. Because large numbers of hypertensive patients continue to suffer from adverse cardiovascular events despite treatment with drugs that robustly inhibit the renin-angiotensin system, the availability of nextgeneration ARBs that protect against cardiovascular disease by doing more than just blocking AT1 receptors could be of significant clinical value. Several next-generation ARBs specifically sought to have added effects beyond just AT1 receptor blockade are currently in development and could hold considerable promise for improving cardiovascular protection in patients with hypertension. 24 
